Presentation is loading. Please wait.

Presentation is loading. Please wait.

OTIS ANNUAL RESEARCH MEETING JUNE 2010 Asthma and Asthma Medications in Pregnancy Study A Vaccines and Medications in Pregnancy Survelliance System (VAMPSS)

Similar presentations


Presentation on theme: "OTIS ANNUAL RESEARCH MEETING JUNE 2010 Asthma and Asthma Medications in Pregnancy Study A Vaccines and Medications in Pregnancy Survelliance System (VAMPSS)"— Presentation transcript:

1 OTIS ANNUAL RESEARCH MEETING JUNE 2010 Asthma and Asthma Medications in Pregnancy Study A Vaccines and Medications in Pregnancy Survelliance System (VAMPSS) Project

2 VAMPSS Project Vaccines and Medications in Pregnancy Surveillance System “VAMPSS” A Collaboration of: American Academy of Allergy Asthma and Immunology Organization of Teratology Information Specialist (OTIS) Slone Epidemiology Center at Boston University (SEC)

3 VAMPSS Project VAMPSS is a new nationwide post-marketing surveillance system established to comprehensively monitor the use and safety of vaccines and medications during pregnancy The VAMPSS system provides a coordinated effort involving: 1. prospective registry surveillance coordinated by OTIS 2. case-control surveillance coordinated by SEC

4 Asthma and Asthma Medications in Pregnancy Study-A VAMPSS Project Study began in November 2009 Prospective, observational cohort study Coordinating center is at the University of California, San Diego

5 Purpose The Asthma and Asthma Medications in Pregnancy study is researching the effects of short-acting and long-acting beta agonists used for the treatment of asthma in pregnancy

6 Study Participation Self-enrollment 4-5 phone interviews (intake, 20wk, 32wk, outcome, and 6 month post-partum) Medical records pertaining to the pregnancy and outcome of the pregnancy

7 Total Enrollment to Date Total as of June 7, 2010 Short-acting Beta- agonists 9 Long-acting Beta- agonists 13 Controls13 Total Enrolled35

8 Who Should be Referred? GroupsCriteria Short-Acting Beta Agonist Diagnosed with asthma Exposure to a short-acting beta agonist Less than 20 weeks gestation Long-Acting Beta Agonist Diagnosed with asthma Exposure to a long-acting beta agonist (Formoterol or Salmeterol) Less than 20 weeks gestation Non-Disease Controls Pregnant women who are less than 20 weeks gestation

9 How to Refer? Toll-free number at 877-311-8972 to refer patient OR provide the patient our toll-free number Contact via email at d4johnson@ucsd.edu Fax a referral sheet to OTIS which is found on our website at www.otispregnancy.org


Download ppt "OTIS ANNUAL RESEARCH MEETING JUNE 2010 Asthma and Asthma Medications in Pregnancy Study A Vaccines and Medications in Pregnancy Survelliance System (VAMPSS)"

Similar presentations


Ads by Google